• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

TRIP13 通过增强 DNA 损伤修复和抑制细胞凋亡诱导食管鳞癌对奈达铂耐药。

TRIP13 Induces Nedaplatin Resistance in Esophageal Squamous Cell Carcinoma by Enhancing Repair of DNA Damage and Inhibiting Apoptosis.

机构信息

Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou, 515041 Guangdong Province, China.

Institute of Oncologic Pathology, Shantou University Medical College, Shantou, 515041 Guangdong Province, China.

出版信息

Biomed Res Int. 2022 May 10;2022:7295458. doi: 10.1155/2022/7295458. eCollection 2022.

DOI:10.1155/2022/7295458
PMID:35601150
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9115607/
Abstract

Thyroid hormone receptor interactor 13 (TRIP13) plays a crucial role in poor prognosis and chemotherapy resistance of cancer patients. This present study is aimed at investigating the role of high expression of TRIP13 inducing nedaplatin (NDP) resistance in esophageal squamous cell carcinoma (ESCC) cells. High expression of TRIP13 promoted the proliferation and migration of ESCC cells performed by MTS assay, colony formation assay, wound healing assay, and transwell assay. High TRIP13 expression induced NDP resistance to ESCC based on the cell proliferation promoting/inhibition rate and cell migration promoting/inhibition rate analysis, flow cytometry assay of apoptotic subpopulations with a combination of Annexin V-FITC and propidium iodide, and Western blot analysis downregulating cleaved PARP, H2A.X, cleaved caspase-3, and Bax and upregulating Bcl-2 expression. This study indicated that high expression of TRIP13 promoted proliferation and migration of ESCC cells and induced NDP resistance via enhancing repair of DNA damage and inhibiting apoptosis. This will provide a preliminary reference for the clinical use of NDP in ESCC treatment.

摘要

甲状腺激素受体相互作用蛋白 13（TRIP13）在癌症患者的不良预后和化疗耐药中发挥着关键作用。本研究旨在探讨 TRIP13 高表达诱导奈达铂（NDP）耐药在食管鳞状细胞癌（ESCC）细胞中的作用。MTS 检测、集落形成实验、划痕愈合实验和 Transwell 实验表明，TRIP13 高表达促进 ESCC 细胞的增殖和迁移。根据细胞增殖促进/抑制率和细胞迁移促进/抑制率分析、结合 Annexin V-FITC 和碘化丙啶的凋亡亚群流式细胞术分析以及下调 cleaved PARP、H2A.X、cleaved caspase-3 和 Bax 并上调 Bcl-2 表达的 Western blot 分析，高 TRIP13 表达诱导 ESCC 对 NDP 的耐药性。本研究表明，TRIP13 高表达通过增强 DNA 损伤修复和抑制细胞凋亡促进 ESCC 细胞的增殖和迁移，并诱导 NDP 耐药。这将为 NDP 在 ESCC 治疗中的临床应用提供初步参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9115607/731843c96f5d/BMRI2022-7295458.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9115607/709d3601476f/BMRI2022-7295458.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9115607/6bf00bfb2140/BMRI2022-7295458.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9115607/552e25c3924f/BMRI2022-7295458.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9115607/ad175e40ade9/BMRI2022-7295458.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9115607/1bfa23581365/BMRI2022-7295458.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9115607/4898ce41dca5/BMRI2022-7295458.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9115607/731843c96f5d/BMRI2022-7295458.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9115607/709d3601476f/BMRI2022-7295458.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9115607/6bf00bfb2140/BMRI2022-7295458.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9115607/552e25c3924f/BMRI2022-7295458.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9115607/ad175e40ade9/BMRI2022-7295458.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9115607/1bfa23581365/BMRI2022-7295458.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9115607/4898ce41dca5/BMRI2022-7295458.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9115607/731843c96f5d/BMRI2022-7295458.007.jpg

相似文献

1
TRIP13 Induces Nedaplatin Resistance in Esophageal Squamous Cell Carcinoma by Enhancing Repair of DNA Damage and Inhibiting Apoptosis.TRIP13 通过增强 DNA 损伤修复和抑制细胞凋亡诱导食管鳞癌对奈达铂耐药。
Biomed Res Int. 2022 May 10;2022:7295458. doi: 10.1155/2022/7295458. eCollection 2022.
2
Thyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinoma.甲状腺激素受体相互作用蛋白 13（TRIP13）过表达与肺腺癌的肿瘤进展和不良预后相关。
Biochem Biophys Res Commun. 2018 May 15;499(3):416-424. doi: 10.1016/j.bbrc.2018.03.129. Epub 2018 Mar 30.
3
TRIP13 upregulation is correlated with poor prognosis and tumor progression in esophageal squamous cell carcinoma.TRIP13 的上调与食管鳞状细胞癌的不良预后和肿瘤进展相关。
Pathol Res Pract. 2019 Jun;215(6):152415. doi: 10.1016/j.prp.2019.04.007. Epub 2019 Apr 17.
4
LncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1.长链非编码 RNA-TUSC7/miR-224 通过竞争性调节 DESC1 影响食管鳞癌细胞的化疗耐药性。
J Exp Clin Cancer Res. 2018 Mar 12;37(1):56. doi: 10.1186/s13046-018-0724-4.
5
Upregulation of thyroid hormone receptor interactor 13 is associated with human hepatocellular carcinoma.甲状腺激素受体相互作用蛋白 13 的上调与人类肝细胞癌有关。
Oncol Rep. 2018 Dec;40(6):3794-3802. doi: 10.3892/or.2018.6767. Epub 2018 Oct 4.
6
MicroRNA-153-3p regulates cell proliferation and cisplatin resistance via Nrf-2 in esophageal squamous cell carcinoma.微小 RNA-153-3p 通过 Nrf-2 调控食管鳞癌细胞增殖和顺铂耐药性。
Thorac Cancer. 2020 Mar;11(3):738-747. doi: 10.1111/1759-7714.13326. Epub 2020 Feb 3.
7
Downregulation of AAA-domain-containing protein 2 restrains cancer stem cell properties in esophageal squamous cell carcinoma via blockade of the Hedgehog signaling pathway.下调 AAA 结构域蛋白 2 通过阻断 Hedgehog 信号通路抑制食管鳞癌细胞中的癌症干细胞特性。
Am J Physiol Cell Physiol. 2020 Jul 1;319(1):C93-C104. doi: 10.1152/ajpcell.00133.2019. Epub 2019 Nov 20.
8
Circular RNA circNTRK2 facilitates the progression of esophageal squamous cell carcinoma through up-regulating NRIP1 expression via miR-140-3p.环状 RNA circNTRK2 通过上调 miR-140-3p 表达促进食管鳞癌细胞的进展。
J Exp Clin Cancer Res. 2020 Jul 11;39(1):133. doi: 10.1186/s13046-020-01640-9.
9
miR-133a-3p suppresses cell proliferation, migration, and invasion and promotes apoptosis in esophageal squamous cell carcinoma.miR-133a-3p 抑制食管鳞癌细胞的增殖、迁移和侵袭，并促进其凋亡。
J Cell Physiol. 2019 Aug;234(8):12757-12770. doi: 10.1002/jcp.27896. Epub 2018 Dec 10.
10
Long non-coding RNA LINC00675 inhibits tumorigenesis and EMT via repressing Wnt/β-catenin signaling in esophageal squamous cell carcinoma.长链非编码 RNA LINC00675 通过抑制食管鳞癌细胞中的 Wnt/β-catenin 信号通路抑制肿瘤发生和 EMT。
Eur Rev Med Pharmacol Sci. 2018 Dec;22(23):8288-8297. doi: 10.26355/eurrev_201812_16526.

引用本文的文献

1
Interactions of Nedaplatin with Nucleobases and Purine Alkaloids: Their Role in Cancer Therapy.奈达铂与核碱基和嘌呤生物碱的相互作用：它们在癌症治疗中的作用。
Biomedicines. 2025 Jun 25;13(7):1551. doi: 10.3390/biomedicines13071551.
2
Discovery of novel antimyeloma agents targeting TRIP13 by molecular modeling and bioassay.通过分子建模和生物测定发现靶向TRIP13的新型抗骨髓瘤药物
RSC Med Chem. 2025 May 6. doi: 10.1039/d4md01008f.
3
Repeated ionizing radiation exposure induces TRIP13 expression, conferring radioresistance in lung cancer cells.

本文引用的文献

1
Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review.食管鳞状细胞癌的免疫检查点抑制剂：一篇叙述性综述
Ann Transl Med. 2020 Sep;8(18):1193. doi: 10.21037/atm-20-4625.
2
Predictive value of EGF and uPAR for chemoradiotherapy response and survival in patients with esophageal squamous cell carcinoma.表皮生长因子（EGF）和尿激酶型纤溶酶原激活物受体（uPAR）对食管鳞状细胞癌患者放化疗反应及生存的预测价值
Ann Transl Med. 2020 Sep;8(18):1152. doi: 10.21037/atm-20-4503.
3
TERT promoter regulating melittin expression induces apoptosis and G/G cell cycle arrest in esophageal carcinoma cells.
反复暴露于电离辐射会诱导TRIP13表达，赋予肺癌细胞放射抗性。
Sci Rep. 2025 Jan 6;15(1):985. doi: 10.1038/s41598-024-84592-w.
4
Role of TRIP13 in human cancer development.TRIP13 在人类癌症发展中的作用。
Mol Biol Rep. 2024 Oct 22;51(1):1088. doi: 10.1007/s11033-024-10012-x.
5
TRIP13 Activates Glycolysis to Promote Cell Stemness and Strengthen Doxorubicin Resistance of Colorectal Cancer Cells.TRIP13 通过激活糖酵解促进结直肠癌细胞干性并增强多柔比星耐药性。
Curr Med Chem. 2024;31(22):3397-3411. doi: 10.2174/0109298673255498231117100421.
6
Targeting TRIP13 for overcoming anticancer drug resistance (Review).靶向 TRIP13 克服抗癌药物耐药性（综述）。
Oncol Rep. 2023 Nov;50(5). doi: 10.3892/or.2023.8639. Epub 2023 Oct 6.
7
Identification of molecular subtypes, risk signature, and immune landscape mediated by necroptosis-related genes in non-small cell lung cancer.非小细胞肺癌中由坏死性凋亡相关基因介导的分子亚型、风险特征及免疫格局的鉴定
Front Oncol. 2022 Jul 28;12:955186. doi: 10.3389/fonc.2022.955186. eCollection 2022.
端粒酶逆转录酶（TERT）启动子调控蜂毒肽表达诱导食管癌细胞凋亡和G/G期细胞周期阻滞
Oncol Lett. 2021 Jan;21(1):16. doi: 10.3892/ol.2020.12277. Epub 2020 Nov 6.
4
Docetaxel and nedaplatin twice a week with concurrent definitive radiotherapy in inoperable esophageal squamous cell carcinoma: A phase I trial (GASTO-1021).每周两次多西他赛和奈达铂联合根治性放疗治疗不可切除食管鳞癌的Ⅰ期临床试验（GASTO-1021）。
Radiother Oncol. 2021 Feb;155:105-112. doi: 10.1016/j.radonc.2020.10.035. Epub 2020 Nov 2.
5
Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study.重组人血管内皮抑制素联合紫杉醇/奈达铂治疗复发性或转移性晚期食管鳞癌的前瞻性、单臂、开放标签、Ⅱ期临床研究。
Invest New Drugs. 2021 Apr;39(2):516-523. doi: 10.1007/s10637-020-01021-1. Epub 2020 Oct 18.
6
High vs. Low Radiation Dose of Concurrent Chemoradiotherapy for Esophageal Carcinoma With Modern Radiotherapy Techniques: A Meta-Analysis.现代放疗技术下食管癌同步放化疗高剂量与低剂量辐射的比较：一项荟萃分析
Front Oncol. 2020 Aug 4;10:1222. doi: 10.3389/fonc.2020.01222. eCollection 2020.
7
Postoperative short-term outcomes of minimally invasive versus open esophagectomy for patients with esophageal cancer: An updated systematic review and meta-analysis.微创手术与开放手术治疗食管癌患者的术后短期结局：一项更新的系统评价和荟萃分析。
Thorac Cancer. 2020 Jun;11(6):1465-1475. doi: 10.1111/1759-7714.13413. Epub 2020 Apr 20.
8
The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents.五种铂类抗肿瘤药物的耐药机制
Front Pharmacol. 2020 Mar 20;11:343. doi: 10.3389/fphar.2020.00343. eCollection 2020.
9
Elevated TRIP13 drives cell proliferation and drug resistance in bladder cancer.TRIP13水平升高促进膀胱癌的细胞增殖和耐药性。
Am J Transl Res. 2019 Jul 15;11(7):4397-4410. eCollection 2019.
10
Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.食管和胃食管交界处癌，2019 年第 2 版，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2019 Jul 1;17(7):855-883. doi: 10.6004/jnccn.2019.0033.